Search
Bayer HealthCare Links
Bayer Dermatology
Company Brochure
Annual Report
Press portal
Clinical trials
Information about clinical studies is available at database of
HealthCare Links
News
-
2012-01-27 |
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older
2012-01-27 |
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older
Bayer HealthCare successfully completed the procedure to get approval for use of the contrast medium Gadovist® 1.0 in children aged two to six years in the Europe Union and markets like Germany, France, Spain, Italy and UK. more
-
2012-01-18 |
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
2012-01-18 |
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
-
2012-01-10 | Cancer
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
2012-01-10 | Cancer
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 more
-
2012-01-09 | Bayer HealthCare Pharmaceuticals
Bayer HealthCare to Share Lab Space with Start-Up Companies
2012-01-09 | Bayer HealthCare Pharmaceuticals
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start more
-
2011-12-22 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
2011-12-22 | Worldnews
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy more
